AAD 2025: Galderma's Dermatology Portfolio Update Highlights Category Leadership and Strong Momentum

Galderma, a leading dermatology company, is set to present extensive updates from across its broad portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11 in Orlando, Florida. With 22 e-posters, including two oral presentations, Galderma will showcase its innovative products and reinforce its status as the pure-play category leader in dermatology. The company's updates span its Dermatological Skincare and Injectable Aesthetics portfolios, highlighting its commitment to research and development and its strong momentum in the market.

New data on Nemluvio® (nemolizumab) will be presented, reinforcing its benefit for a broad range of patients with prurigo nodularis and atopic dermatitis. An oral presentation on Friday, March 7, will report new data on the efficacy of Nemluvio treatment up to Week 16 across different pruriginous lesion types in patients with prurigo nodularis from the phase III OLYMPIA program. Additionally, data demonstrating the continuous response with Nemluvio up to 56 weeks in patients with moderate-to-severe atopic dermatitis who had a partial or no response to treatment at Week 16 in the ARCADIA 1&2 trials and long-term extension study will be shared.

Real-world evidence on atopic dermatitis will also be presented, including an oral e-poster presentation with findings from a retrospective analysis of access disparities for atopic dermatitis patients across ethnic groups using the U.S. Medicaid database on Sunday, March 9. Furthermore, data exploring the association between itch severity and initiation of biologic therapy will be shared.

On Sunday, March 9, Galderma will host an Industry Session Theatre titled 'Targeting the IL-31 Neuroimmune Pathway: Transforming Itch and Inflammation Outcomes'. Presented by Dr. Jonathan Silverberg and Dr. Sarina Elmariah, this patient and expert panel discussion will delve into the crucial need to address neuroimmune interactions with atopic dermatitis and prurigo nodularis, the impact of IL-31, and how a targeted treatment improves real patient outcomes.

Galderma will also present the latest data from across its Injectable Aesthetics portfolio, including updates on Restylane, Sculptra, and Relfydess. Interim data from a study exploring the benefits of Restylane Lyft or Contour with Sculptra in patients with medication-driven weight loss with associated facial volume loss will be shared. Results from a comparative study evaluating the synergistic effects for midface improvement when pairing Sculptra with a skincare regimen will also be presented, as well as a comparative analysis of suggested genetic pathways affected by Sculptra vs another biostimulator, and consensus and evidence-based recommendations on the impact of minimally invasive treatments on subsequent facial surgery for additional aesthetic enhancement.

Additional data from Galderma's Restylane portfolio includes the first ever ultrasound comparison of the tissue integration, dynamic support, and lifting capacity of Restylane Contour versus another rheologically different hyaluronic acid filler. Data from an AI-enabled Manufacturer and User Facility Device Experience database analysis of delayed complications with hyaluronic acid fillers will also be presented.

In conclusion, Galderma's extensive updates from across its dermatology portfolio at the 2025 AAD Annual Meeting underscore its category leadership and strong momentum in the market. With new data on Nemluvio, updates on Restylane, Sculptra, and Relfydess, and real-world evidence on atopic dermatitis, Galderma continues to demonstrate its commitment to innovation, research and development, and addressing the evolving needs of its patients and healthcare providers.